CA3116612A1 - Peptide fragments for treatment of diabetes - Google Patents

Peptide fragments for treatment of diabetes Download PDF

Info

Publication number
CA3116612A1
CA3116612A1 CA3116612A CA3116612A CA3116612A1 CA 3116612 A1 CA3116612 A1 CA 3116612A1 CA 3116612 A CA3116612 A CA 3116612A CA 3116612 A CA3116612 A CA 3116612A CA 3116612 A1 CA3116612 A1 CA 3116612A1
Authority
CA
Canada
Prior art keywords
peptide
seq
fol
amino acid
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3116612A
Other languages
English (en)
French (fr)
Inventor
Jan Alenfall
Maria EKBLAD
Pontus Duner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Follicum AB
Original Assignee
Follicum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Follicum AB filed Critical Follicum AB
Publication of CA3116612A1 publication Critical patent/CA3116612A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3116612A 2018-11-07 2019-11-07 Peptide fragments for treatment of diabetes Pending CA3116612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18204862 2018-11-07
EP18204862.9 2018-11-07
PCT/EP2019/080563 WO2020094797A1 (en) 2018-11-07 2019-11-07 Peptide fragments for treatment of diabetes

Publications (1)

Publication Number Publication Date
CA3116612A1 true CA3116612A1 (en) 2020-05-14

Family

ID=64183928

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3116612A Pending CA3116612A1 (en) 2018-11-07 2019-11-07 Peptide fragments for treatment of diabetes

Country Status (13)

Country Link
US (2) US20220002343A1 (https=)
EP (1) EP3876970A1 (https=)
JP (1) JP7553115B2 (https=)
KR (1) KR20210088583A (https=)
CN (1) CN113164548A (https=)
AU (1) AU2019374981A1 (https=)
BR (1) BR112021008888A2 (https=)
CA (1) CA3116612A1 (https=)
IL (1) IL282519A (https=)
MX (1) MX2021005386A (https=)
SG (1) SG11202104276YA (https=)
WO (1) WO2020094797A1 (https=)
ZA (1) ZA202102572B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218095A1 (en) * 2022-05-13 2023-11-16 Coegin Pharma Ab Agents for stimulating tissue regeneration
JP2025516717A (ja) * 2022-05-13 2025-05-30 コーギン ファーマ エービー 血管新生を誘発する薬剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10505750A (ja) * 1994-09-16 1998-06-09 ザ スクリップス リサーチ インスティテュート 粘着および軸索の成長を刺激するサイトタクチン誘導体並びにその製造および使用方法
WO2004015390A2 (en) 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
CN100503637C (zh) * 2004-04-14 2009-06-24 浙江贝达药业有限公司 胰高血糖素样肽类似物、其组合物及其使用方法
US9044438B2 (en) * 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
EP2114422A1 (en) * 2007-03-02 2009-11-11 National University of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
GB201406989D0 (en) * 2014-04-17 2014-06-04 Follicum Ab Novel treatments
CA3061935A1 (en) * 2017-05-04 2018-11-08 Follicum Ab Peptides for treatment of diabetes

Also Published As

Publication number Publication date
AU2019374981A1 (en) 2021-05-27
SG11202104276YA (en) 2021-05-28
BR112021008888A2 (pt) 2021-08-17
KR20210088583A (ko) 2021-07-14
ZA202102572B (en) 2022-10-26
US20240327459A1 (en) 2024-10-03
IL282519A (en) 2021-06-30
US20220002343A1 (en) 2022-01-06
WO2020094797A1 (en) 2020-05-14
JP2022516400A (ja) 2022-02-28
EP3876970A1 (en) 2021-09-15
MX2021005386A (es) 2021-07-06
JP7553115B2 (ja) 2024-09-18
CN113164548A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
US10815283B2 (en) Peptides for treatment of diabetes
US20240327459A1 (en) Peptide fragments for treatment of diabetes
JP3262329B2 (ja) 糖尿病治療に有用なｇｌｐ―１アナログ
ES2334864T5 (es) Péptido-2 de tipo glucagón y su uso terapéutico
RU2206336C2 (ru) Фрагмент с-пептида человеческого проинсулина
JPH04507240A (ja) インシュリン様成長因子及び類似体を用いる障害治療方法
Castel et al. Biochemical and functional characterization of high‐affinity urotensin II receptors in rat cortical astrocytes
PT2212349E (pt) Análogos sintéticos de péptidos de regeneração neural
EP4648849A1 (en) Nmu receptor 2 agonists
US20160002310A1 (en) Modified ingap peptides for treating diabetes
HK40017988B (en) Peptides for treatment of diabetes
HK40017988A (en) Peptides for treatment of diabetes
Do SunGil et al. Silk fibroin hydrolysate exerts an anti-diabetic effect by increasing pancreatic β cell mass in C57BL/KsJ-db/db mice.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106